1. Home
  2. AROW vs LRMR Comparison

AROW vs LRMR Comparison

Compare AROW & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arrow Financial Corporation

AROW

Arrow Financial Corporation

HOLD

Current Price

$33.02

Market Cap

529.9M

Sector

Finance

ML Signal

HOLD

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

HOLD

Current Price

$4.62

Market Cap

455.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AROW
LRMR
Founded
1851
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
529.9M
455.8M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
AROW
LRMR
Price
$33.02
$4.62
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$28.00
$16.50
AVG Volume (30 Days)
82.8K
2.5M
Earning Date
04-30-2026
03-19-2026
Dividend Yield
3.60%
N/A
EPS Growth
49.72
N/A
EPS
2.65
N/A
Revenue
N/A
N/A
Revenue This Year
$33.36
N/A
Revenue Next Year
$18.26
$1,368.04
P/E Ratio
$12.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.72
$1.61
52 Week High
$36.44
$6.42

Technical Indicators

Market Signals
Indicator
AROW
LRMR
Relative Strength Index (RSI) 47.89 50.57
Support Level $31.14 $3.09
Resistance Level $33.30 $5.37
Average True Range (ATR) 0.77 0.36
MACD 0.10 -0.08
Stochastic Oscillator 67.68 21.94

Price Performance

Historical Comparison
AROW
LRMR

About AROW Arrow Financial Corporation

Arrow Financial Corp is a holding company. It provides various advisory and administrative services and coordinates the general policies and operations of the banks. It provides financial products, including online and mobile banking, mortgages, commercial loans, investments, and others. The company also provides lending services, including commercial and industrial lending to small and mid-sized companies; mortgage lending for residential and commercial properties; and consumer installment and home equity financing. The key source of the company's revenue is interest income, fees, commission earned through its subsidiaries.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: